Quick answer
A blend certificate should do three things a single-peptide certificate does not: identify each of the three components separately, show that the chromatography can tell them apart, and state a lot number that matches the vial. For the Glow Stack, the mass accounting is 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 = 70 mg total, and the cake and solution should show the blue of intact copper binding. A single combined purity figure does not prove that each peptide is intact, and the name TB-500 covers more than one sequence, so identity must be read from the certificate. For laboratory research use only; not for human consumption.
Buying a blend adds verification work that a single peptide does not need. There are three analytes in one vial, one of them a metal complex, and a certificate that reports one purity number leaves most questions open. This checklist is built for the people who receive the material: what to ask of the documentation, what to inspect when the vial arrives, what simple arithmetic confirms that the label is self-consistent and what to write down. It is a quality procedure for laboratory work, and it makes no claim about biological effects. Composition comes from the Glow Stack product page, and a broader discussion of where a research peptide should come from is in where to buy the Glow Stack for research.
What the product page commits to
The product page lists a 70 mg total with a 50 / 10 / 10 split, purity of at least 98% measured by HPLC, a batch-specific certificate published online for lot ARC-GL70-002, and a list of items the documentation covers: compound identity and sequence, measured purity, sequence or identity confirmation, batch and lot number, analytical test date and supplied form with storage. For the sequence of the blend, it states that identity is reported on the certificate of analysis where published. These commitments are the baseline against which a certificate is checked.
Component-level questions for a blend certificate
| Question | Why a blend needs it | What a satisfactory answer looks like |
|---|---|---|
| Is each component identified separately? | One vial hides three analytes | Separate identity entries for GHK-Cu, BPC-157 and TB-500 |
| Does the HPLC method resolve all three? | Overlapping peaks can hide each other | A chromatogram in which the three main peaks are distinct, or a stated method for each |
| Is purity stated per component or only overall? | 98% overall does not guarantee 98% of each | Per-component values, or a clear statement of how the overall figure was derived |
| Is mass confirmed for each peptide? | Retention time alone does not prove sequence | Observed masses that match the expected ones |
| Is copper addressed? | The complex is the species under study for GHK-Cu | A statement of copper binding or content where reported |
| Does the lot number match the vial? | Traceability | Exact match to the label |
| Is the test date given? | Stability context | Date present and plausible relative to production |
The method and the logic of each field are explained in how to read a COA, understanding HPLC purity and HPLC vs mass spectrometry. The reason to insist on per-component information is that HPLC purity is a share of chromatographic signal and does not give net peptide content or identify a peak by itself.
The TB-500 naming problem
The name TB-500 is used for different thymosin beta-4-derived sequences. The published wound literature includes full-length thymosin beta-4 and the seven-residue actin-binding fragment LKKTETQ, which in aged mice promoted repair comparably to the parent molecule (Philp and colleagues, 2003). A researcher who cites thymosin beta-4 work for a lot that contains only a fragment, or the reverse, is making an assumption that the certificate should either support or contradict. Therefore, read the identity entry for TB-500 first and record the sequence or mass found. The comparison between the research names is covered in TB-500 vs thymosin beta-4.
Mass accounting: does the label add up?
A short calculation checks that the label is internally consistent. The three stated masses should sum to the stated total, and the molar amounts show how different the components are, which is useful when planning concentrations.
| Component | Label mass | Approx. molecular weight (g/mol) | Approx. amount (µmol) |
|---|---|---|---|
| GHK-Cu (complex) | 50 mg | about 404 | about 124 |
| BPC-157 | 10 mg | about 1,419.5 | about 7.0 |
| TB-500 (7-residue fragment) | 10 mg | about 889 | about 11.2 |
| Total | 70 mg | — | — |
The amounts follow from mass divided by molecular weight and assume 100% peptide content, which is an upper bound, because counter-ions and residual water make net content lower. The GHK-Cu share is the dominant one by mass (about 71%) and even more by moles, about 124 µmol against 7.0 and 11.2, so a certificate that presented the three as equal-weight components would be misleading. If the TB-500 on the certificate has a different mass from the fragment value used here, recompute from the certificate figure.
Receiving inspection
- Packaging. Sealed clear glass vial, intact cap and crimp, no leakage, label legible and lot number matching the certificate.
- Cake. Pale blue to blue lyophilized material is consistent with a copper-containing blend. A collapsed or wet-looking cake, a green or brown tint, or visible foreign matter should be recorded before use.
- Temperature on arrival. Note transit time and whether the vial was warm. The product page storage line is 2–8 °C with −20 °C for long-term holding, protected from heat, moisture and light.
- Documentation. Download the certificate for the lot and file it with the receipt record.
- Photograph. One photo of the vial and label on arrival makes later comparisons far easier.
A broken cake in transit is cosmetic, but a solid that looks sticky or discolored deserves a note. For what is normal after reconstitution, see peptide vial appearance and cloudy peptide vial after reconstitution.
Documentation red flags
| Observation | Why it matters | Reasonable response |
|---|---|---|
| A single purity figure and no chromatogram | Nothing shows what was measured or how | Ask for the trace and method before relying on the number |
| Identical-looking certificates across different products | Suggests a template and not lot-specific data | Check lot numbers, dates and values for differences |
| No mass confirmation | Retention time alone does not prove identity | Request mass data or test independently |
| Lot number on the certificate differs from the vial | Breaks traceability | Do not use until resolved |
| Test date long before the vial's production | Stability and relevance questions | Ask for the date of testing for this lot |
| Component masses on the certificate that do not sum to the label | Label inconsistency | Recompute and query the difference |
None of these proves a problem on its own, but each is a reason to slow down and gather information before the material goes into an experiment, and each is cheap to check at the receiving bench.
Checks at the reconstitution stage
The second inspection point is when the cake meets diluent. The solution should be clear and uniformly blue with no particles, strands or lasting foam. Dissolving should be gentle, by swirling or rolling, not shaking. Use a diluent without chelators or phosphate, record the volume added and compute each component's concentration separately (component mass divided by volume), since the three differ by a factor of five in mass. A worked example: 70 mg in 5 mL gives 10 mg/mL GHK-Cu and 2 mg/mL of each of the other two, and a 2 mL fill gives 25 mg/mL and 5 mg/mL. If the solution is cloudy, green or brown, or if blue color fades over days in storage, record the observation with the date and consider the stock compromised. Because color reports only on the copper complex, a normal color does not confirm the other two peptides, which are colorless and can be verified only analytically. The storage tiers and the reasoning are in GLOW peptide reconstitution and storage.
Verifying the blend yourself
When an experiment is sensitive to composition, an independent check is reasonable. Reversed-phase HPLC with a gradient suited to a tripeptide complex and two larger peptides, followed by mass spectrometry on each peak, confirms that all three are present and shows relative peak areas. Copper content can be assessed by an elemental method. Run a reference of the same lot at time zero, then repeat on stored aliquots to detect change (see the storage guidance in storing research peptides). Copper-catalyzed oxidation is a recognized damage route for amino-acid residues in peptides and proteins (Stadtman and Levine, 2003), and surface adsorption can lower dilute concentrations (Goebel-Stengel and colleagues, 2011), so verification should use low-binding labware. The coordination chemistry of the GHK-Cu part is covered in the article on what GHK-Cu is (Hureau and colleagues, 2011).
What to record for each lot
| Field | Entry |
|---|---|
| Product and lot | Glow Stack, lot number from the label |
| Certificate | File name, test date, method summary |
| Arrival | Date, condition of vial, cake color, transit notes |
| Composition check | Label masses summed; any difference from the certificate noted |
| Reconstitution | Date, diluent, volume, concentration of each component |
| Storage | Location and temperature; freeze count of each aliquot |
| Independent testing | Method, result and date, if performed |
This record is what turns a certificate into evidence for your own work. Keep it in the same place as the raw data of the experiment, so that anyone reviewing a result can see which material produced it, what its documentation said and how it was handled between receipt and use. When a lot is finished, note the last use date as well, because a later question about a result is easier to answer if the start and end of the lot's life are both on file. Where a lot-specific certificate has been published, it is on the COA page, and the calculation of per-component concentrations is in the reconstitution calculator.
Related reading
- GLOW peptide blend overview
- Where to buy the Glow Stack for research
- How to read a COA
- Peptide blends and research stacks
- BPC-157 and TB-500 third-party testing
- Research peptide catalog
Frequently asked questions
What should a COA for a peptide blend include?
Separate identity for each component, an HPLC method that resolves them, per-component purity or a clear statement of how overall purity was derived, mass confirmation, lot number and test date.
Why is 98% overall purity not enough for a blend?
It is a share of total chromatographic signal and does not show the purity of each component, nor net peptide content.
What is in the Glow Stack vial by mass?
The product page lists 70 mg total: 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500.
What color should the Glow Stack be?
The cake is expected to be pale blue to blue because of the copper complex, and the solution clear blue. Haze, green or brown tints should be recorded and the stock set aside.
Why check the TB-500 identity on the certificate?
The name is used for different thymosin beta-4-derived sequences, and a paper on one may not apply to another.
How should the vial be stored on arrival?
The product page states 2–8 °C, or −20 °C for long-term storage, protected from heat, moisture and light.
Can I verify the blend independently?
Yes. HPLC with mass spectrometry on each peak confirms presence and relative amounts, and an elemental method can assess copper. Use low-binding labware and compare against a time-zero reference.
Related reading: Glow Stack Research Guide: Component Reference Sheet, Glow Stack Storage: Copper Compatibility Troubleshooting, Glow Stack Synergy: How to Test It in the Lab.
References
- Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. doi:10.1046/j.1524-475x.2003.11105.x
- Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids. 2003;25(3-4):207-18. doi:10.1007/s00726-003-0011-2
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
- Hureau C, Eury H, Guillot R, Bijani C, Sayen S, Solari PL, et al.. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chemistry. 2011;17(36):10151-60. doi:10.1002/chem.201100751
- Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012;2012:324832. doi:10.1155/2012/324832
